CAJ | 학술논문

1例80岁男性晚期食管癌患者因失去手术机会且放弃放、化疗,给予白细胞介素100万U入0.9％氯化钠注射液100 ml静脉滴注,1次/d;复方苦参注射液15 ml入0.9％氯化钠注射液250 ml静脉滴注,1次/d;雷尼替丁注射液50 mg入壶,2次/d.用药前实验室检查示丙氨酸转氨酶(ALT) 44 U/L,天冬氨酸转氨酶(AST)24 U/L,胆碱酯酶(CHE) 388 U/L,总胆红素(TBil) 29.2 μmol/L,直接胆红素(DBil)7.3 μmol/L,间接胆红素(IBil)21.9 μmol/L.用药4d后ALT 72 U/L、AST 71U/L、γ-L-谷氨酰转移酶(γ-GT)74 U/L、CHE 3387 U/L,继而出现恶心、呕吐和黄疸等症状;用药29 d后ALT 83 U/L,AST 67 U/L,γ-GT 597 U/L,CHE 2734 U/L,碱性磷酸酶(ALP) 151 U/L,TBil203.0 mol/L,DBil 102.5 mol/L,IBil 100.5 mol/L,白蛋白(ALB) 32.6g/L.停用复方苦参注射液,给予保肝治疗.1个月后,患者恶心、呕吐及黄疸等症状缓解,复查肝功能:ALT 15 U/L,AST 21U/L,γ-GT59 U/L,ALP 66 U/L,TBil 46.1 mol/L,DBil 16.2 mol/L,IBil 29.9 mol/L.
1례80세남성만기식관암환자인실거수술궤회차방기방、화료,급여백세포개소100만U입0.9％록화납주사액100 ml정맥적주,1차/d;복방고삼주사액15 ml입0.9％록화납주사액250 ml정맥적주,1차/d;뢰니체정주사액50 mg입호,2차/d.용약전실험실검사시병안산전안매(ALT) 44 U/L,천동안산전안매(AST)24 U/L,담감지매(CHE) 388 U/L,총담홍소(TBil) 29.2 μmol/L,직접담홍소(DBil)7.3 μmol/L,간접담홍소(IBil)21.9 μmol/L.용약4d후ALT 72 U/L、AST 71U/L、γ-L-곡안선전이매(γ-GT)74 U/L、CHE 3387 U/L,계이출현악심、구토화황달등증상;용약29 d후ALT 83 U/L,AST 67 U/L,γ-GT 597 U/L,CHE 2734 U/L,감성린산매(ALP) 151 U/L,TBil203.0 mol/L,DBil 102.5 mol/L,IBil 100.5 mol/L,백단백(ALB) 32.6g/L.정용복방고삼주사액,급여보간치료.1개월후,환자악심、구토급황달등증상완해,복사간공능:ALT 15 U/L,AST 21U/L,γ-GT59 U/L,ALP 66 U/L,TBil 46.1 mol/L,DBil 16.2 mol/L,IBil 29.9 mol/L.
An 80-year-old man with unresectable advanced esophageal cancer who gave up radiotherapy and chemotherapy received an Ⅳ infusion of 1 million U interleukin dissolved in 100 ml of 0.9％ sodium chloride once daily,15 ml compound matrine injection dissolved in 250 ml of 0.9％ sodium chloride once daily,and 50 ml ranitidine injection into the Ⅳ drip bulb twice daily.Before treatment,laboratory tests showed the following values:alanine aminotransferase (ALT) 44 U/L,aspartate aminotransferase (AST) 24 U/L,cholinesterase (CHE) 388 U L,total bilirubin (TBil) 29.2 μmol/L,direct bilirubin (DBil) 7.3 μmol/L,and indirect bilirubin (IBil) 21.9 μmol/L.On day 4 of treatment,laboratory tests showed the following values:ALT 72 U/L,AST 71 U/L,γ-glutamyl transferase (γ-GT) 74 U/L,CHE 3387 U/L,and developed nausea,vomiting and aurigo.On day 29 of treatment,laboratory tests showed the following values:AST 67 U/L,γ-GT 597 U/L,CHE 2734 U/L,alkaline phosphatase (ALP) 151 U/L,TBil 203.0 mol/L,DBil 102.5 mol/L,IBil 100.5 mol/L,albumin (ALB) 32.6 g/L.The compound matrine injection was withdrawn and the liver-protective treatment was given.One month later,his symptoms of nausea,vomiting and aurigo were mitigated and liver function reexamination showed the following values:ALT 15 U/L,AST 21 U/L,γ-GT 59 U/L,ALP 66 U/L,TBil 46.1 mol/L,DBil 16.2 mol/L,IBil 29.9 mol/L.